In small cell lung cancer (SCLC), Koyen et al. reported that EZH2 has a non-catalytic, PRC2-independent role in stabilizing DDB2, a DNA repair factor, to promote nucleotide excision repair (NER) and cisplatin resistance in SCLC (Figure 3e) [80]. This evidence concerns the gene DDB2 and small cell lung carcinoma.